Current Edition

CAR-T cell therapy

Gilead’s Kite enters leukemia with Tecartus FDA approval, overlapping Novartis’ CAR-T rival Kymriah

Gilead Sciences’ Kite Pharma has expanded its second CAR-T cell therapy, Tecartus, into a leukemia market that overlaps a Novartis territory for Kymirah. The FDA …

Continue Reading →